{
    "id": 32734,
    "fullName": "EGFR G983_G1054del",
    "impact": "deletion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EGFR G983_G1054del results in the deletion of 72 amino acids in the protein kinase and cytoplasmic domain of the Egfr protein from amino acids 983 to 1054 (PMID: 25826094). G983_G1054del (reported as exon25,26del) results in constitutive phosphorylation of Egfr, Stat3, and Akt, is transforming in cell culture, and promotes tumor growth in mouse models (PMID: 25826094, PMID: 22980975).",
            "references": [
                {
                    "id": 18089,
                    "pubMedId": 25826094,
                    "title": "Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25826094"
                },
                {
                    "id": 1726,
                    "pubMedId": 22980975,
                    "title": "Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22980975"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "G983_G1054del",
    "createDate": "03/10/2020",
    "updateDate": "03/10/2020",
    "referenceTranscriptCoordinates": {
        "id": 188311,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55201189_55201783del595",
        "cDna": "c.2948_3162+1del595",
        "protein": "p.G983_G1054del72",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20839,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and viability of transformed cells expressing EGFR G983_G1054del (reported as exon25,26del) in culture, and suppressed tumor growth in cell line xenograft models (PMID: 25826094).",
            "molecularProfile": {
                "id": 35364,
                "profileName": "EGFR G983_G1054del"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18089,
                    "pubMedId": 25826094,
                    "title": "Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25826094"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20837,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited EGFR signaling and viability of transformed cells expressing EGFR G983_G1054del (reported as exon25,26del) in culture, and suppressed tumor growth in cell line xenograft models (PMID: 25826094).",
            "molecularProfile": {
                "id": 35364,
                "profileName": "EGFR G983_G1054del"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18089,
                    "pubMedId": 25826094,
                    "title": "Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25826094"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20840,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) inhibited EGFR signaling and viability of transformed cells expressing EGFR G983_G1054del (reported as exon25,26del) in culture (PMID: 25826094).",
            "molecularProfile": {
                "id": 35364,
                "profileName": "EGFR G983_G1054del"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18089,
                    "pubMedId": 25826094,
                    "title": "Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25826094"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20838,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited EGFR signaling and viability of transformed cells expressing EGFR G983_G1054del (reported as exon25,26del) in culture, and suppressed tumor growth in cell line xenograft models (PMID: 25826094).",
            "molecularProfile": {
                "id": 35364,
                "profileName": "EGFR G983_G1054del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18089,
                    "pubMedId": 25826094,
                    "title": "Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25826094"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35364,
            "profileName": "EGFR G983_G1054del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 188311,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55201189_55201783del595",
            "cDna": "c.2948_3162+1del595",
            "protein": "p.G983_G1054del72",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}